ByTrending Posts
Can AstraZeneca’s 2025 Launches and Approvals Strengthen Its…
Global | January 2026 — AstraZeneca PLC achieved significant milestones in 2025, marked by multiple regulatory approvals, label…
Can Novo Nordisk’s 2025 Diabetes, Obesity, and Rare…
Global | January 2026 — Novo Nordisk A/S continued to reinforce its leadership in diabetes, obesity, and rare…
Can Roche’s 2025 Launches and Approvals Reinforce Its…
Global | January 2026 — Roche Holding AG achieved a strong year in 2025, marked by multiple regulatory…
Can Novartis’ 2025 Approvals and Launches Strengthen Its…
Global | January 2026 — Novartis AG advanced its strategic portfolio in 2025 with multiple product approvals and…
Can Johnson & Johnson’s 2025 Product Momentum and…
Global | January 2026 — Johnson & Johnson continued to reinforce its position as one of the world’s…
Can Gilead’s 2025 Approvals and Targeted Launches Reinforce…
Global | January 2026 — Gilead Sciences, Inc. strengthened its innovation-led growth profile in 2025 through a focused…
Can AbbVie’s 2025 Launches and Portfolio Expansion Offset…
Global | January 2026 — AbbVie Inc. accelerated its post-Humira transformation in 2025, advancing a diversified portfolio across…
Can Merck’s 2025 Launches, Label Expansions, and Oncology…
Global | January 2026 — Merck & Co., Inc. (MSD outside the U.S. and Canada) reinforced its position…
Can Eli Lilly’s 2025 Brand Launches and Label…
Global | January 2026 — Eli Lilly and Company accelerated its transformation in 2025 through a series of…
Trending Posts
Latest Stories
Can Eli Lilly’s Orforglipron Overtake Novo Nordisk’s Rybelsus in the Race for Oral GLP-1 Leadership?
Indianapolis, Ind., 2026 — Eli Lilly and Company today announced positive head-to-head Phase 3 results…
Is Bayer’s Lawsuit Against Johnson & Johnson Escalating the Competitive Battle in Prostate Cancer Therapeutics?
Leverkusen, Germany — Bayer AG has filed a lawsuit in U.S. federal court against Johnson…
Is Johnson & Johnson’s $1 Billion Pennsylvania Investment a Defining Bet on the Future of Cell Therapy?
New Brunswick, N.J. — Johnson & Johnson today announced plans to invest more than $1…
Is Johnson & Johnson Preparing to Divest DePuy Synthes in a $20 Billion Strategic Pivot Toward Pharmaceuticals?
Will Johnson & Johnson’s Orthopedics Review Reshape the Global MedTech Landscape? Johnson & Johnson is…
Gallery
